Title:
CDKL5 EXPRESSION VARIANTS AND CDKL5 FUSION PROTEINS
Document Type and Number:
WIPO Patent Application WO/2019/108924
Kind Code:
A3
Abstract:
Novel CDKL5 enzyme variants are provided, as well as fusion proteins comprising full-length CDKL5 polypeptides or CDKL5 variants. Such fusion proteins can include cell-penetrating polypeptides and optionally comprising a leader signal polypeptide and/or tags. Also provided are methods of producing such CDKL5 variants and fusion proteins, as well as pharmaceutical compositions, methods of treatment, and uses of such recombinant proteins.
More Like This:
| WO/2022/234051 | SPLIT PRIME EDITING ENZYME |
| WO1998050530 | ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATED TO LEVELS OF EXPRESSION OF C-RAF |
| WO/2007/088171 | CERAMIDE KINASE LOOP |
Inventors:
CLARK SEAN (US)
Application Number:
PCT/US2018/063294
Publication Date:
August 15, 2019
Filing Date:
November 30, 2018
Export Citation:
Assignee:
AMICUS THERAPEUTICS INC (US)
International Classes:
C12N9/12
Domestic Patent References:
| WO2005072470A2 | 2005-08-11 | |||
| WO2015128746A2 | 2015-09-03 |
Other References:
CHEN ET AL.: "CDKL5, a protein associated with Rett Syndrome, regulates neuronal morphogenesis via Racl signaling", J NEUROSCI, vol. 30, 22 September 2010 (2010-09-22), pages 12777 - 12786, XP002790819
Attorney, Agent or Firm:
ALEGRIA, Rory (US)
Download PDF: